Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1488-1493

  Chandran, Rekha ^a   Gardiner, Stuart K ^b   Simon, Miklos ^c   Spurgeon, Stephen E ^d  

^a Legacy Health System   (United States)

^b DEVERS EYE INSTITUTE   (United States)

^c Northwest Cancer Specialists   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Mantle cell lymphoma; prognostic factors; SEER database; survival trends

Indexed keywords

CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84864229997     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.656628     Document Type: Article

References (22)

1. Onciu M, Schlette E, Medeiros LJ, et al. Cytogenetic fi ndings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol 2001;116:886-892.
2. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma.-Rfaut proposal for unifi cation of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637-640.
3. Harris NL, Jaff e ES, Stein H, et al. A revised European-American classifi cation of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994;84:1361-1392.
4. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791-798.
5. Decaudin D, Bosq J, Tertian G, et al. Phase II trial of fl udarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998;16:579-583.
6. F oran JM, Rohatiner AZ, Coiffi er B, et al. Multicenter phase II study of fl udarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546-553.
7. de Guibert S, Jaccard A, Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as fi rst-line therapy for mantle cell lymphoma. Haematologica 2006; 91:425-426.
8. R omaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantlecell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
9. Geisler CH, Kolstad A, Laurell A, et al. Long-term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
10. H errmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
11. S chmidt C, Dreyling M. Th erapy of mantle cell lymphoma: current standards and future strategies. Hematol Oncol Clin North Am 2008;22:953 - 963, ix.
12. L eitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003;14:1555-1561.
13. R ummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is eff ective in the treatment of mantlecell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002;38:1739-1746.
14. H oward OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-1294.
15. E pner EM, Unger J, Miller T. A multi center trial of hyper CVAD- rituxan in patients with newly diagnosed cell lymphoma. Blood 2007;110(Suppl. 1): Abstract 387.
16. SEER Research Data1973 - 2007: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973 - 2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. [Internet]. Available from: www.seer. cancer.gov
17. A ndersen NS, Jensen MK, de Nully Brown P, et al. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401-408.
18. V elders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14: 1269-1274.
19. Riihijarvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011;86:124-128.
20. P al SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010;28:4086-4093.
21. C larke CA, Undurraga DM, Harasty PJ, et al. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006;15:630-638.
22. Zhou Y, Zhang L, Romaguera J, et al. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 2008;83:144-149